Singapore, March 25 -- The Health Sciences Authority received information related to the study titled 'A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the effects of oral TRPC6 inhibitor BI 764198 taken over a 104 week treatment period in adult and adolescent participants with primary focal segmental glomerulosclerosis (pFSGS) or genetic FSGS related to TRPC6 gene variants'. The following are the other relevant details related to the trial:
Therapeutic Area: Renal Medicine
Trial Centre(s):
National University Hospital
Singapore General Hospital
Tan Tock Seng Hospital
Trial Status: Not Yet Recruiting
Principal Investigator(s):
Dr Chan Gek Cher
Dr Lee Tung Lin
Dr Yeo See Cheng
Published by HT ...